Jetema Co., Ltd.’s clinical investigation evaluating the safety and efficacy of the medical device JTM102 for mid-face volume deficiency is moving forward in the clinical trials process. This trial, which also includes comparator data using Juvederm VOLUMA with Lidocaine, remains active but is no longer recruiting participants as of December 8, 2025. Regulatory and clinical stakeholders should note this important milestone for aesthetic and reconstructive medicine.
What is the current progress of the trial?
As of the publication date, the clinical trial investigating JTM102 for mid-face volume deficiency remains active but is no longer recruiting additional participants. This indicates that all necessary patient enrollment is complete, allowing researchers to focus on data collection and analysis.
The trial’s goal is to evaluate the safety and efficacy of JTM102, a dermal filler device developed by Jetema Co., Ltd. Data from the study may provide critical insights into the device’s performance compared to the established Juvederm VOLUMA with Lidocaine.
Which devices are being evaluated?
Two devices are central to this investigation:
- JTM102: A dermal filler device under development by Jetema Co., Ltd. This device aims to address mid-face volume loss and improve facial aesthetics.
- Juvederm VOLUMA with Lidocaine: A widely recognized dermal filler that incorporates lidocaine for added patient comfort during use. This device serves as the comparator in this trial.
Both devices are being assessed for their ability to safely and effectively restore mid-face volume. This approach ensures robust evidence to inform both clinical and regulatory decisions.
What are the implications for regulatory compliance?
This trial underscores the importance of adhering to medical device regulatory frameworks. Jetema Co., Ltd., as the trial sponsor, is likely conducting the study under Good Clinical Practice (GCP) standards and relevant medical device regulations, such as MDR Annex XIV.
If successful, the trial data could support a regulatory submission for market authorization in jurisdictions where mid-face volume deficiency is a recognized indication. Clinical and regulatory teams monitoring these developments should prepare for potential device labeling, safety reporting, and performance claims.
For clinicians, these results could expand treatment options for patients suffering from age-related or disease-induced mid-face volume loss.
FAQs
1. What condition does this trial aim to address?
The trial targets mid-face volume deficiency, a condition that can result from aging, certain medical conditions, or trauma.
2. Who sponsors this clinical trial?
The trial is sponsored by Jetema Co., Ltd., a company specializing in aesthetic and medical devices.
3. What is the status of the trial?
The trial is active but no longer recruiting. This indicates that enough participants have enrolled for the study’s objectives.
4. What do the results aim to determine?
The study seeks to establish the safety and effectiveness of JTM102 compared to Juvederm VOLUMA with Lidocaine in addressing mid-face volume deficiencies.
Conclusion
This clinical trial represents a pivotal step in evaluating innovative solutions for mid-face volume loss. Regulatory, clinical, and quality professionals should continue to monitor outcomes as they could shape future device approvals and clinical practices in aesthetic medicine.
Disclaimer
This article is intended for informational purposes only and is not legal or regulatory advice. Professionals should consult appropriate guidelines and regulatory bodies for specific advice.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07265778?term=medical+device